Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial

Apolipoprotein B ◽

Controlled Trial ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Dipeptidyl peptidase-4 inhibitor improves glycemic variability in multiple daily insulin-treated type 2 diabetes: a prospective randomized-controlled trial

Diabetology International ◽

10.1007/s13340-021-00513-6 ◽

2021 ◽

Author(s):

Fukumi Yoshikawa ◽

Hiroshi Uchino ◽

Tomoko Nagashima ◽

Shuki Usui ◽

Masahiko Miyagi ◽

...

Keyword(s):

Type 2 Diabetes ◽

Prospective Randomized Controlled Trial

Controlled Trial ◽

Glycemic Variability ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

Diabetology & Metabolic Syndrome ◽

10.1186/1758-5996-4-36 ◽

2012 ◽

Vol 4 (1) ◽

Cited By ~ 47

Author(s):

Robert Frederich ◽

Robert McNeill ◽

Niklas Berglind ◽

Douglas Fleming ◽

Roland Chen

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Controlled Trial ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Treatment Naïve

Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

10.1111/dom.12802 ◽

2016 ◽

Vol 19 (2) ◽

pp. 200-207 ◽

Cited By ~ 17

Author(s):

Michael A. Nauck ◽

Melanie Kahle ◽

Oleg Baranov ◽

Carolyn F. Deacon ◽

Jens J. Holst

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Effects of Ezetimibe/Simvastatin 10/20 mg vs. Atorvastatin 20 mg on Apolipoprotein B/Apolipoprotein A1 in Korean Patients with Type 2 Diabetes Mellitus: Results of a Randomized Controlled Trial

American Journal of Cardiovascular Drugs ◽

10.1007/s40256-013-0031-6 ◽

2013 ◽

Vol 13 (5) ◽

pp. 343-351 ◽

Cited By ~ 7

Author(s):

Ju-Hee Lee ◽

Hyun-Jae Kang ◽

Hyo-Soo Kim ◽

Dae-Won Sohn ◽

Byung-Hee Oh ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Apolipoprotein B ◽

Controlled Trial ◽

Apolipoprotein A1 ◽

Korean Patients ◽

Randomized Controlled

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial ( STOP‐OB )

10.1111/dom.14059 ◽

2020 ◽

Vol 22 (9) ◽

pp. 1659-1663 ◽

Cited By ~ 1

Author(s):

Toru Kitazawa ◽

Hiroaki Seino ◽

Hiroshi Ohashi ◽

Takeshi Inazawa ◽

Masahiro Inoue ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Oral Agent ◽

Open Label ◽

Dipeptidyl Peptidase 4 ◽

The Third ◽

Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study)

Diabetes Therapy ◽

10.1007/s13300-020-00941-8 ◽

2020 ◽

Vol 11 (12) ◽

pp. 2959-2977

Author(s):

Hitoshi Ishii ◽

Hiroki Nakajima ◽

Nozomu Kamei ◽

Tetsuji Niiya ◽

Toru Hiyoshi ◽

...

Keyword(s):

Quality Of Life ◽

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitors

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes

10.1111/dom.12988 ◽

2017 ◽

Vol 19 (11) ◽

pp. 1602-1609 ◽

Cited By ~ 7

Author(s):

Ira Gantz ◽

Taro Okamoto ◽

Yuka Ito ◽

Kotoba Okuyama ◽

Edward A. O'Neill ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Safety And Efficacy ◽

Dipeptidyl Peptidase 4 ◽

Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8‐week, randomized, controlled, double‐blind trial

10.1111/dom.14107 ◽

2020 ◽

Vol 22 (10) ◽

pp. 1847-1856

Author(s):

Jordan Kraaijenhof ◽

Marcel H. A. Muskiet ◽

Lennart Tonneijck ◽

D. Margriet Ouwens ◽

Mark H. H. Kramer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Dipeptidyl Peptidase ◽

Double Blind Trial ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Blind Trial ◽

Randomized Controlled ◽

Intervention of the Flash Glucose Sensing Technology on Glycemic Control and Treatment Satisfaction in Patients with Type 2 Diabetes Treated Intensively by Insulin—A Randomized Controlled Trial

Diabetes ◽

10.2337/db18-908-p ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 908-P ◽

Cited By ~ 1

Author(s):

MARIANNA YARON ◽

EYTAN ROITMAN ◽

GENYA AHARON-HANANEL ◽

ZOHAR LANDAU ◽

TALI GANZ ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Treatment Satisfaction ◽

Controlled Trial ◽

Glucose Sensing ◽

Randomized Controlled ◽

Sensing Technology

110-LB: The Korean Titration: A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Self-Titration Algorithms of Insulin Glargine 300 Units/ml in Patients with Uncontrolled Type 2 Diabetes

Diabetes ◽

10.2337/db20-110-lb ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 110-LB

Author(s):

JAE HYUN BAE ◽

CHANG HO AHN ◽

YE SEUL YANG ◽

SUN JOON MOON ◽

SOO HEON KWAK ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Controlled Trial ◽

Efficacy And Safety ◽

Randomized Controlled